Citing pandemic, Sarepta defers much-anticipated DMD gene therapy PhIII, will head to regulators after 10-person study

When Sarepta disclosed in September that the FDA held up their widely-anticipated Phase III trial over an assay, the big question was whether …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cit­ing pan­dem­ic, Sarep­ta de­fers much-an­tic­i­pat­ed DMD gene ther­a­py PhI­II, will head to reg­u­la­tors af­ter 10-per­son study